Scott B. Ullem - May 7, 2022 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, Chief Financial Officer
Signature
Linda J. Park, Attorney-in-Fact
Stock symbol
EW
Transactions as of
May 7, 2022
Transactions value $
-$954,940
Form type
4
Date filed
5/10/2022, 08:53 PM
Previous filing
May 5, 2022
Next filing
May 17, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Tax liability -$77.6K -772 -2.98% $100.52 25.1K May 7, 2022 Direct
transaction EW Common Stock Options Exercise $0 +14.8K +59.06% $0.00 39.9K May 8, 2022 Direct F1
transaction EW Common Stock Tax liability -$877K -8.73K -21.85% $100.52 31.2K May 8, 2022 Direct
holding EW Common Stock 245K May 7, 2022 By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Performance Rights Options Exercise $0 -14.8K -100% $0.00* 0 May 8, 2022 Common Stock 14.8K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On May 8, 2019, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 2, 2022, the Compensation Committee of the Board of Directors determined that 175% of the target number of shares would vest as of May 8, 2022, and the actual number of shares vested are reflected on this Form 4.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.